Innovent Biologics Announces Phase 3 Success for Mazdutide in Treating Type 2 Diabetes

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of on...

July 22, 2024 | Monday | News
Teva Pharmaceuticals’ AJOVY Achieves Primary End Point in Pediatric Phase 3 Migraine Study

SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to ...

July 19, 2024 | Friday | News
Shanghai Junshi Biosciences' sNDA for Toripalimab and Bevacizumab Combo for Advanced Liver Cancer Accepted by NMPA

  Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...

July 19, 2024 | Friday | News
China's NMPA Approves First and Only Subcutaneous FcRn Blocker for gMG Patients

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigim...

July 16, 2024 | Tuesday | News
Rznomics Inc. Receives Approval for Phase 1/2a Clinical Trial of RZ-004 in Australia

Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced that it has receive...

July 15, 2024 | Monday | News
Eisai and Biogen Announce Approval of Alzheimer’s Treatment LEQEMBI® in Israel

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher...

July 12, 2024 | Friday | News
BioArctic AB’s Partner Eisai Announces Approval of Leqembi® (樂意保®) for Alzheimer’s Disease Treatment in Hong Kong

BioArctic AB  is pleased to announce that its partner, Eisai, has received approval from the Department of Health in Hong Kong for Leqembi® (bra...

July 11, 2024 | Thursday | News
Certara to Acquire Chemaxon, Expanding Biosimulation Capabilities in Drug Discovery

Certara, Inc.  a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leadi...

July 10, 2024 | Wednesday | News
Certara to Acquire Chemaxon, Expanding Biosimulation Capabilities in Drug Discovery

Certara, Inc.  a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leadi...

July 10, 2024 | Wednesday | News
Apriori Bio Secures $1.1 Million from CEPI to Enhance AI-Driven Vaccine Platform Against Evolving Viruses

Biotechnology company Apriori Bio has been awarded US $1.1 million from CEPI to advance its biology-informed artificial intelligence platform Octavi...

July 09, 2024 | Tuesday | News
Myricx Bio Secures £90m Series A Funding Co-Led by Novo Holdings and Abingworth

£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital...

July 08, 2024 | Monday | News
Iktos Acquires Synsight, Gains Exclusive License to INSERM's AI-Driven Screening Technology

Synsight provides Iktos with an exclusive worldwide license to INSERM’s patented technology enabling high performance AI-driven in cellulo screen...

July 08, 2024 | Monday | News
Roche's Vabysmo® Prefilled Syringe Gains FDA Approval for Major Eye Conditions

Roche  announced  that the United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6.0 mg single-dose pre...

July 05, 2024 | Friday | News
Boehringer Ingelheim and OSE Immunotherapeutics Advance SIRPα Immuno-Oncology Program to Phase 1b Clinical Trials

Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company (ISIN: FR0012127173; Mnemo: OSE), announced that Boehringer wi...

July 04, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close